Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.2, beating the estimate of USD -0.3013.

EBIT: As of FY2026 Q2, the actual value is USD -18.12 M.

Financial Results for Q2 2026 and Six Months Ended June 30, 2026

Cash, Cash Equivalents, and Short-Term Investments

As of June 30, 2026, Whitehawk Therapeutics, Inc. reported cash, cash equivalents, and short-term investments of $190.0 million, an increase from $145.7 million as of December 31, 2025. This balance is expected to fund operations into the second half of 2028.

Research and Development Expenses

For the three months ended June 30, 2026, research and development expenses were $12.9 million, a decrease from $48.8 million for the same period in 2025, which included a $38.0 million up-front license fee paid to WuXi Biologics. For the six months ended June 30, 2026, these expenses totaled $30,125 thousand, down from $57,597 thousand in the comparable period of 2025.

Net Loss

Whitehawk Therapeutics, Inc. reported a net loss of - $16.6 million for the three months ended June 30, 2026, an improvement from a net loss of - $52.6 million for the three months ended June 30, 2025. For the six months ended June 30, 2026, the net loss was - $38,834 thousand, compared to a net income of $20,401 thousand for the six months ended June 30, 2025.

Total Operating Expenses

Total operating expenses for the three months ended June 30, 2026, were $18,109 thousand, significantly lower than $54,749 thousand for the same period in 2025. For the six months ended June 30, 2026, total operating expenses were $41,631 thousand, down from $77,112 thousand in the prior year period.

Loss from Operations

Loss from operations was - $18,109 thousand for the three months ended June 30, 2026, compared to - $54,749 thousand for the corresponding period in 2025. For the six months ended June 30, 2026, the loss from operations was - $41,631 thousand, an improvement from - $69,967 thousand for the six months ended June 30, 2025.

Comprehensive Loss

Comprehensive loss for the three months ended June 30, 2026, was - $16,685 thousand, compared to - $52,607 thousand for the same period in 2025. For the six months ended June 30, 2026, comprehensive loss was - $39,017 thousand, while the company reported comprehensive income of $20,394 thousand for the six months ended June 30, 2025.

Other Financial Data

• Selling, General and Administrative Expenses: $5,216 thousand for Q2 2026 compared to $5,940 thousand for Q2 2025; $11,506 thousand for the six months ended June 30, 2026, compared to $18,755 thousand for the six months ended June 30, 2025.
• Interest Income: $1,475 thousand for Q2 2026 compared to $1,979 thousand for Q2 2025; $2,803 thousand for the six months ended June 30, 2026, compared to $2,770 thousand for the six months ended June 30, 2025.
• Total Assets: $193,994 thousand as of June 30, 2026, compared to $150,830 thousand as of December 31, 2025.
• Total Liabilities: $11,069 thousand as of June 30, 2026, compared to $14,519 thousand as of December 31, 2025.
• Total Stockholders’ Equity: $182,925 thousand as of June 30, 2026, compared to $136,311 thousand as of December 31, 2025.

Operational Metrics

Whitehawk Therapeutics, Inc. completed an $87.5 million private placement equity financing in May 2026.

Outlook

Whitehawk Therapeutics, Inc. plans to initiate a Phase 1 study for HWK-206 in Q3 2026. Initial results from the HWK-007 and HWK-016 Phase 1 trials are expected in the first half of 2027. The company anticipates submitting Investigational New Drug (IND) applications for multiple new programs over the next 12-24 months.